CN1673234A - 裂裥八糖烷基苷类化合物及其制备方法 - Google Patents
裂裥八糖烷基苷类化合物及其制备方法 Download PDFInfo
- Publication number
- CN1673234A CN1673234A CN 200510020122 CN200510020122A CN1673234A CN 1673234 A CN1673234 A CN 1673234A CN 200510020122 CN200510020122 CN 200510020122 CN 200510020122 A CN200510020122 A CN 200510020122A CN 1673234 A CN1673234 A CN 1673234A
- Authority
- CN
- China
- Prior art keywords
- preparation
- grams
- schizo
- milliliters
- glycoside compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 229930182470 glycoside Natural products 0.000 title claims abstract description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 27
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 5
- 239000012454 non-polar solvent Substances 0.000 claims abstract description 5
- 239000003054 catalyst Substances 0.000 claims abstract description 3
- 239000000376 reactant Substances 0.000 claims abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 32
- -1 alkyl glycoside compound Chemical class 0.000 claims description 11
- 150000001720 carbohydrates Chemical class 0.000 claims description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 claims description 4
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims description 4
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 229910052796 boron Inorganic materials 0.000 claims description 2
- 125000001033 ether group Chemical group 0.000 claims description 2
- 239000011968 lewis acid catalyst Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 6
- 239000002841 Lewis acid Substances 0.000 abstract 1
- 150000007517 lewis acids Chemical class 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 43
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- 238000007670 refining Methods 0.000 description 12
- 239000000741 silica gel Substances 0.000 description 12
- 229910002027 silica gel Inorganic materials 0.000 description 12
- 229960001866 silicon dioxide Drugs 0.000 description 12
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 229920002305 Schizophyllan Polymers 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 9
- 239000012141 concentrate Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 230000006837 decompression Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical class CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 150000003538 tetroses Chemical class 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920001491 Lentinan Polymers 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 229940115286 lentinan Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000003222 pyridines Chemical class 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 101100391174 Dictyostelium discoideum forC gene Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229920000519 Sizofiran Polymers 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- KJRCEJOSASVSRA-UHFFFAOYSA-N propane-2-thiol Chemical class CC(C)S KJRCEJOSASVSRA-UHFFFAOYSA-N 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 229950001403 sizofiran Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical class CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了一种具有抗肿瘤作用的裂裥八糖烷基苷类化合物,其结构通式为:本发明同时提供的该类化合物的制备方法为采用糖供体和糖受体为反应物,以路易斯酸作催化剂,在非极性溶剂中利用醚键将两者结合在一起。
Description
(一)技术领域
本发明是关于有生物活性的,特别是涉及有可能用作医药的裂裥八糖烷基苷类化合物及其制备方法。
(二)背景技术
裂裥多糖(Sizofiran)是从裂裥菌提取的多糖,是与香菇多糖齐名的中药抗癌药物,裂裥多糖在日本已成为注册药物。据报道,裂裥多糖对肺癌、胃癌、宫颈癌、卵巢癌等有显著的治疗作用,在部分施用了裂裥多糖的患者身上还发现了肿瘤细胞消失或显著减少的现象,特别是对无法进行胃切除的胃癌患者,施用裂裥多糖可大大延长存活时间(参见K.Tabata,Carbohydyate Research,1981,89,P121-135.)。
研究认为,裂裥多糖的抑制肿瘤作用是通过人体的免疫系统来实现的,机体中免疫活性细胞的种类主要有单核巨噬细胞系统、淋巴细胞系统和粒细胞系统等。当机体具有正常的生理功能时,这些免疫活性细胞能吞噬并清除衰亡突变细胞(如癌细胞)、各种病原体(如细菌、真菌、寄生虫)等。部分专家认为,人人体内都有癌细胞存在。带有癌细胞的健康人不患癌症主要是因为人体中的免疫活性细胞的存在使癌细胞的繁殖速度与清除衰亡细胞速度处于一个动态平衡状态,若这一动态平衡因机体免疫系统的损伤而破坏,则癌细胞的繁殖速度就会大大高于被吞噬清除的速度,表现为癌症的发作。普通的化疗药物没有专一性,在杀害肿瘤细胞的同时也将大量正常细胞杀死,对人体有较大的毒副作用,也损伤了患者的元气,增添了病人完全康复的难度。裂裥多糖的抗癌作用不是通过直接杀死癌细胞,它是通过宿主中介而起作用,即刺激机体的各种免疫活性细胞的成熟、分化和繁殖,使机体免疫系统恢复平衡,由机体的本身抗体去清除、吞噬癌细胞,它对人体细胞无任何毒害作用。
最新研究表明:寡糖具有与相应多糖相似或更优良的生理功能,如抗癌药物香菇多糖的核心结构片段-香菇寡糖(六糖)-具有比香菇多糖更优良的抗癌活性(参见Jun Ning,WenhuiZhang,Yuetao Yi,Guangbin Yang,Zhikui Wu,Jie Yi,Fanzuo Kong,Bioorg.Med.Chem.2003,11/10,2193-2203)。
(三)发明内容
所以,本发明的第一个目的是提供一类含有裂裥多糖结构重复单元的裂裥八糖烷基苷类化合物,该类化合物具有化学结构明确,易于大量合成,易于质量控制等裂裥多糖不可比拟的优点,具备取代裂裥多糖用于制药和保健品领域的良好前景。
本发明的第二个目的是提供上述裂裥八糖烷基苷类化合物的合成方法。
首先,本发明提供了一种具有如下通式结构的裂裥八糖烷基苷类化合物,
式中:n为1-18的整数。
本发明采用糖供体和糖受体为反应物,以路易斯酸作催化剂,在非极性溶剂中利用醚键将两者结合在一起。
为了更好地实现其目的,本发明的路易斯酸催化剂为常用的三氟化硼-乙醚、三甲基硅三氟甲磺酸酯、N-碘代丁二酰亚胺,非极性溶剂为乙醚、乙腈、二氯甲烷、甲苯。
(五)具体实施方式
下面结合实施例对本发明进行详细地说明。
实施例
裂裥八糖十二烷基苷的制备
1、四糖供体9的制备:
(1)单糖受体5的制备
在反应器中,加入乙酸酐150毫升、无水乙酸钠15克,在搅拌、加热回流的同时,小心分批加入无水葡萄糖1(18.0克,0.10摩尔),回流2小时后减压蒸出大部分乙酸酐,往所得剩余物中加入300毫升冰水,然后用乙酸乙酯萃取3次(每次50毫升),乙酸乙酯液依次用水、饱和碳酸氢钠溶液和水洗至中性,无水硫酸钠干燥,减压蒸出溶剂后得白色固体2(35.9克),产率92%。
在反应器中,加入2(19.5克,0.05摩尔)、二氯甲烷80毫升、异丙硫醇7毫升、三氟化硼乙醚13毫升,室温搅拌反应1小时,加二氯甲烷100毫升稀释,用饱和碳酸氢钠溶液中和,饱和食盐水洗3次,浓缩后上硅胶柱精制,用石油醚/乙酸乙酯(2/1)作为淋洗液,收集相应组分,得到3(16.3克),产率80%。
在反应器中,加入3(16.3克,0.04摩尔)、无水甲醇150毫升,通氨饱和,放置3小时,浓缩后上硅胶柱精制,用乙酸乙酯作为淋洗液,收集相应组分,得到4(9.1克),产率95%。
在反应器中,加入4(8.4克,0.035摩尔)、乙腈40毫升、苯甲醛13毫升、原甲酸三乙酯17毫升、对甲苯磺酸0.9克,室温搅拌反应3小时,用三乙胺中和,浓缩后上硅胶柱精制,用石油醚/乙酸乙酯(3/1)作为淋洗液,收集相应组分,得到5(10.3克),产率90%。
(2)三糖供体6的制备
三糖供体6的制备,在本发明之前已有公开记载,可按公开文献(Jun Ning,Wenhui Zhang,Yuetao Yi,Guangbin Yang,Zhikui Wu,Jie Yi,Fanzuo Kong,Bioorg.Med.Chem.2003,11/10,2193-2203)的方法制备。
(3)四糖供体9的制备
在反应器中,加入5(1.65克,0.005摩尔)、6(7.8克,0.005摩尔)、二氯甲烷50毫升、三甲基硅三氟甲磺酸酯(TMSOTF)30微升,室温搅拌反应3小时,用三乙胺中和,浓缩后上硅胶柱精制,用石油醚/乙酸乙酯(3/1)作为淋洗液,收集相应组分,得到7(7.4克),产率85%。
在反应器中,加入7(6.9克,0.004摩尔)、90%乙酸水溶液40毫升,40℃放置24小时,减压蒸出溶剂后,乙酸乙酯溶样上硅胶柱精制,用石油醚/乙酸乙酯(2/1)作为淋洗液,收集相应组分,得到8(5.8克),产率88%。
在反应器中,加入8(5.7克,3.5毫摩尔)、吡啶20毫升、乙酸酐10毫升,室温搅拌反应2小时,加二氯甲烷80毫升稀释,依次用稀盐酸、饱和碳酸氢钠溶液、饱和食盐水洗,浓缩后上硅胶柱精制,用石油醚/乙酸乙酯(2/1)作为淋洗液,收集相应组分,得到9(5.6克),产率90%。
2、四糖受体15的制备
(1)三糖供体10的制备
三糖供体10的制备,在本发明之前已有公开记载,可按公开文献(Jun Ning,Wenhui Zhang,Yuetao Yi,Guangbin Yang,Zhikui Wu,Jie Yi,Fanzuo Kong,Bioorg.Med.Chem.2003,11/10,2193-2203)的方法制备。
(2)四糖受体15的制备
在反应器中,加入5(3.3克,0.01摩尔)、10(13.1克,0.01摩尔)、二氯甲烷100毫升、三甲基硅三氟甲磺酸酯(TMSOTF)50微升,室温搅拌反应3小时,用三乙胺中和,浓缩后上硅胶柱精制,用石油醚/乙酸乙酯(3/1)作为淋洗液,收集相应组分,得到11(12.3克),产率83%。
在反应器中,加入11(11.8克,0.008摩尔)、90%乙酸水溶液70毫升,40℃放置24小时,减压蒸出溶剂后,乙酸乙酯溶样上硅胶柱精制,用石油醚/乙酸乙酯(2/1)作为淋洗液,收集相应组分,得到12(11.6克),产率88%。
在反应器中,加入12(9.7克,0.007摩尔)、吡啶40毫升、乙酸酐20毫升,室温搅拌反应2小时,加二氯甲烷150毫升稀释,依次用稀盐酸、饱和碳酸氢钠溶液、饱和食盐水洗,浓缩后上硅胶柱精制,用石油醚/乙酸乙酯(2/1)作为淋洗液,收集相应组分,得到13(9.8克),产率92%。[α]D-29.5°(c1.0,CHCl3);1H NMR(CDCl3,400MHz):δ8.01-7.26(m,20H,4Phh),5.87-5.68(m,3H),5.53-5.40(m,2H),5.18-5.10(m,2H),5.03-4.94(m,3H),4.85(m,1H),4.66-4.45(m,4H),4.39-4.20(m,4H),4.03-3.88(m,6H),3.83-3.70(m,4H),3.67-3.45(m,3H),3.18(m,1H),2.11-1.91(m,25H),1.33-1.25(m,6H);13C NMR(100MHz,CDCl3)δ:170.67,170.60,169.57,169.30,169.17,168.96,168.84,168.60(8C,8COCH3),166.05,165.84,165.16,164.99(4C,4COPh),134.09-128.32(Ph,CH2CH=CH2),116.97(CH2CH=CH2),101.25,100.48,100.27(3C,C-1B,1C,1D),83.10(1C,C-1A)。
在反应器中,加入13(9.1克,0.006摩尔)、十二醇(2.3克,0.012摩尔)、二氯甲烷90毫升、氮-碘代丁二酰亚胺(NIS)2.7克、TMSOTF80微升,室温搅拌反应2小时,用三乙胺中和,浓缩后上硅胶柱精制,用石油醚/乙酸乙酯(3/1)作为淋洗液,收集相应组分,得到14(5.5克),产率56%。
在反应器中,加入14(4.9克,0.003摩尔)、二氯甲烷25毫升、无水甲醇50毫升、氯化钯200毫克,室温搅拌反应8小时,过滤,减压蒸出溶剂后,二氯甲烷溶样上硅胶柱精制,用石油醚/乙酸乙酯(1/1)作为淋洗液,收集相应组分,得到15(4.1克),产率86%。13C NMR(100MHz,CDCl3)δ:170.466,170.41,169.66,169.35,169.11,168.93,168.81,168.58(8C,8 COCH3),166.15,165.92,165.14,164.95(4C,4 COPh),133.97-127.92(Ph,),101.07,100.28,100.74,100.54(4C,C-1A,1B,1C,1D),31.77,29.46,20.44,29.36,29.20,29.14,29.11,25.62,22.55,20.89,20.65,20.56,20.51,20.44,20.40,20.24(8C,8 COCH3),14.03。
3、裂裥八糖十二烷基苷的制备
在反应器中,加入15(3.2克,0.002摩尔)、9(3.5克,0.002摩尔)、二氯甲烷50毫升、氮-碘代丁二酰亚胺(NIS)1.0克、TMSOTF30微升,室温搅拌反应2小时,用三乙胺中和,浓缩后上硅胶柱精制,用石油醚/乙酸乙酯(3/1)作为淋洗液,收集相应组分,得到16(3.9克),产率60%。
在反应器中,加入16(3.3克,0.001摩尔)、二氯甲烷30毫升、无水甲醇400毫升、通氨饱和,室温放置10天,用薄层分析检测反应,反应完成后,减压蒸干溶剂,用二氯甲烷洗涤,弃掉洗涤液,得到粉末状产物I(1.4克),产率95%。[α]D15.4°(c1.0,H2O).13C NMR(100MHz,D2O)δ:105.24,105.08,105.07,104.97,104.67,104.46,104.38,101.25(8C-1),31.75,29.44,29.42,29.33,29.18,29.10,25.59,22.54,14.00.Anal.calcd forC60H106O41:C,4 8.58;H,7.16.found:C,48.02;H,7.76。
本发明的其它化合物的制备方法与本实施例相近,本专业的技术人员容易类比得出,在此不再多述。
动物抑瘤试验实例
取昆明小鼠61只、体重24-26g、雌雄兼用。取接种7-8天之腹水瘤按1∶15稀释计数、使终浓度为1000万个S180瘤细胞/ml;每鼠腋下接种0.2ml(含200万个S180瘤细胞)、次日随机均分5组:实施例制备的化合物I4mg/kg、2mg/kg、1mg/kg、空白对照组及环磷酰胺(CY)40mg/kg组,药物组每天给药一次(尾静脉注射iv),连续给药9天,对照组则给予相应体积的生理盐水(NS)液,CY组间日给药一次,末次给药后停药一天,脱颈处死动物、称体重、剖瘤称重、按下公式计算肿瘤抑制率并用t检验比较组间差异。
试验结果:见下表
实施例制备的化合物对S180小鼠的抗肿瘤作用
组别 | 计量(mg/kg) | 途径/次数 | 动物数(只)开始 药后 | 体重(g)开始 药后 | 瘤株 | 瘤重x±sd | 抑瘤率(%) | P值 |
空白组IIICY | -42140 | -iv×9iv×9iv×9sc×9 | 21 2110 1010 1010 1010 10 | 25.0 38.225.2 36.825.1 36.325.0 37.425.1 31.8 | S180S180S180S180S180 | 3.68±1.052.30±0.842.34±0.912.42±0.710.63+0.28 | 37.536.434.282.8 | <0.01<0.01<0.01<0.001 |
从试验结果可见:实施例制备的化合物对荷S180小鼠肿瘤有明显抑制作用(<0.01)。
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200510020122 CN1673234A (zh) | 2005-01-05 | 2005-01-05 | 裂裥八糖烷基苷类化合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200510020122 CN1673234A (zh) | 2005-01-05 | 2005-01-05 | 裂裥八糖烷基苷类化合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1673234A true CN1673234A (zh) | 2005-09-28 |
Family
ID=35046036
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200510020122 Pending CN1673234A (zh) | 2005-01-05 | 2005-01-05 | 裂裥八糖烷基苷类化合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1673234A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107955082A (zh) * | 2017-12-11 | 2018-04-24 | 江南大学 | 幽门螺旋杆菌脂多糖外核心八糖的制备方法 |
-
2005
- 2005-01-05 CN CN 200510020122 patent/CN1673234A/zh active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107955082A (zh) * | 2017-12-11 | 2018-04-24 | 江南大学 | 幽门螺旋杆菌脂多糖外核心八糖的制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yang et al. | Characterization and anti-tumor activity of pollen polysaccharide | |
JP2911554B2 (ja) | 抗ウィルス剤 | |
CN102731365B (zh) | 猴头菌抑制幽门螺杆菌的生物小分子及其在治疗消化道疾病中的应用 | |
CN101224215A (zh) | 熊果酸皂苷、齐墩果酸皂苷在制备升高白细胞和/或血小板药物中的应用 | |
CN1629160A (zh) | 13-已基小檗碱盐的制备及其抗病毒和抗菌作用 | |
CN100469783C (zh) | 一种寡糖及其硫酸化产物和寡糖集簇物以及它们的用途 | |
CN1673234A (zh) | 裂裥八糖烷基苷类化合物及其制备方法 | |
CN1762391A (zh) | 一种牛初乳和香菇提取物组合物及其制备方法和用途 | |
CN1300158C (zh) | 一类非天然活性寡糖类化合物及其制备方法和应用 | |
CN101824065B (zh) | 人参皂苷次级苷Rh1的脂肪酸单酯类化合物及制备方法 | |
CN1957930A (zh) | 和厚朴酚在制备肿瘤化疗增敏剂中的应用 | |
CN1049221C (zh) | 人参寡糖素、人参单体寡糖及其制备工艺和应用 | |
AU2012273838A1 (en) | Multivalent (beta) - 1 - 2 - linked mannose oligosaccharides as immunostimulatory compounds and uses thereof | |
CN1305479C (zh) | 具有抗肿瘤活性的低极性人参皂苷组合物 | |
CN101037466A (zh) | 皂苷类化合物及其制备方法和应用 | |
CN100457766C (zh) | 非天然活性葡聚四糖烷基苷类化合物及其制备方法和应用 | |
CN1137130C (zh) | 裂褶四糖烷基苷类化合物及其制备方法和应用 | |
CN1450075A (zh) | 一类寡糖及其硫酸化产物和它们的制备方法及含该寡糖的药物组合物 | |
JP2010229080A (ja) | iNKT細胞活性化剤 | |
CN1939327A (zh) | 柳川鱼苷、蒙花苷及其组合物的制药用途 | |
WO2002062813A1 (fr) | Nouveau produit presentant une activite physiologique, preparation et utilisation de ce produit | |
CN101381385A (zh) | 一种葡聚四糖烷基苷类化合物的制备方法 | |
CN1083848C (zh) | 果聚糖硫酸酯、合成方法及其应用 | |
CN1243100C (zh) | 壳囊孢菌素b制法及在制备抗肿瘤和抗真菌药物中的应用 | |
CN101712700B (zh) | 一种烷基乳糖苷受体及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |